Effects of glycometide combined with acarbose or metformin on glucose and lipid metabolism as well as islet function in newly diagnosed type 2 diabetes patients

Objective To investigate the effects of glycometide combined with acarbose or metformin on glucose and lipid metabolism as well as islet function in newly diagnosed type 2 diabetes patients. Methods A total of 82 patients newly diagnosed type 2 diabetes were divided into control group(n=41)and observation group(n=41)according to the random number table method. The control group was treated with glimepirea and acarbose, while the observation group(n=41)was treated with glimepirea and metformin. Both groups were treated for 12 weeks. Changes of glucose and lipid metabolism indicators［postprandial blood glucose(2h PG), fasting blood glucose(FBG), glycosylated hemoglobin(HbA1c)and low-density lipoprotein cholesterol(LDL-C), total cholesterol(TC), triglyceride(TG)］, oxidative stress related markers ［reactive oxygen species(ROS), superoxide dismutase(SOD), malondialdehyde(MDA)］ and indicators related to islet function［homeostasis model assessment of insulin resistance(HOMA-IR), β cell function(HOMA-β), insulin sensitivity index(ISI)］ levels were observed before and after treatment in both groups. Results FBG, PG and HbA1c, LDL-C, TC and TG levels after treatment were all decreased in both groups, and the above indexes in the observation group were significantly lower than those in the control group(P<0.05). After treatment, ROS and MDA levels in both groups were significantly decreased, while SOD levels were significantly increased, ROS and MDA levels in the observation group were significantly - lower than those in the control group, while SOD level was significantly higher than that in the control group(P<0.05). After treatment, the levels of HOMA-IR were decreased in both groups, while levels of HOMA-β and ISI were increased compared with treatment before(P<0.05). The levels of HOMA-IR in the observation group were lower than those in the control group, while HOMA-β and ISI levels were higher than those in the control group(P<0.05). Conclusion The efficacy of glymepiridine combined with metformin in the treatment of type 2 diabetes is superior to that of glymepiridine combined with acarbose, and can improve functions of glucose and lipid metabolism as well as islet cell, and relieve the oxidative stress injury.